Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Plecanatide (Trulance) is indicated for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
• The information about plecanatide was derived from a systematic review/meta-analysis, which incorporated data from 33 randomized controlled trials involving over 17,214 patients.
• At different points during the study, other medications such as stimulant diphenyl methane laxatives were found to be most effective at achieving three or more complete spontaneous bowel movements per week after four weeks, while prucalopride was most effective at twelve weeks.
• Although specific comparative data for plecanatide wasn't provided in detail, the study suggests that nearly all studied drugs, including plecanatide, were superior to placebo in improving bowel movement frequency. However, direct comparisons between plecanatide and other treatments regarding safety and efficacy are not explicitly outlined.
• Bisacodyl had the lowest safety profile based on the total number of adverse events and abdominal pain, suggesting potentially better safety profiles for other medications including Trulance (plecanatide), although specific details were not given.
• Prucalopride and linaclotide, along with certain doses of other medications, showed effectiveness specifically among populations who hadn’t responded previously to laxatives, indicating that subgroup considerations play a significant role in the choice of these types of medication.